Looking for Exposure to Johnson & Johnson Stock (JNJ) ahead of Q4 Earnings? Here's How to Buy Without the Risk
I'm PortAI, I can summarize articles.
Johnson & Johnson (JNJ) will report Q4 earnings on January 21, with analysts predicting revenue of $24.16 billion and earnings of $2.49 per share. Investors may consider ETFs like iShares U.S. Pharmaceuticals ETF (IHE) and Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) for exposure to JNJ without direct stock risk. The IHE ETF, which holds 23% of JNJ, has gained 28.09% over six months and has a Moderate Buy consensus rating with a price target suggesting 19.24% upside potential.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments